NovoCure
NVCRNovoCure is a global oncology company that develops and commercializes a proprietary platform technology called Tumor Treating Fields (TTFields).
Earnings
Next report
Date not yet announcedValuation & ratios
Segments
By geography
Competitors
By market cap
By revenue growth
By net margin
Profile
NovoCure is a global oncology company that develops and commercializes a proprietary platform technology called Tumor Treating Fields (TTFields). This therapy utilizes tuned electric fields to exert physical forces that disrupt cancer cell division, providing a non-invasive treatment modality for aggressive solid tumors. The company's primary value proposition is extending overall survival in patients with difficult-to-treat cancers without the systemic toxicity typically associated with chemotherapy.
NovoCure is the pioneer and leading provider of Tumor Treating Fields therapy, holding an extensive global patent portfolio that protects its unique physical mode of action against solid tumors.
Questions, answered.
- What is NovoCure's market cap?
- NovoCure (NVCR) has a market capitalization of $2.0B and trades on NASDAQ.
- What is NovoCure's revenue and profitability?
- NovoCure generated $699.2M in trailing twelve-month revenue with a net loss of $148.6M, representing a net margin of -21.2%. Gross margin stands at 76.1%, with free cash flow of -$25.4M. These figures are based on the Q2 2026 filing.
- Who are NovoCure's competitors?
- NovoCure's key competitors include Medtronic, Boston Scientific, Nuvation Bio Inc., and others. These companies compete in similar markets and product categories.
- Who does NovoCure partner with?
- NovoCure's notable partners include Zai Lab (Shanghai) Co., Ltd., Merck & Co., Inc., Roche.
- Where is NovoCure headquartered?
- NovoCure is headquartered in Jersey and employs approximately 1,453 people. It has been publicly traded since 2015.
